189 related articles for article (PubMed ID: 26306753)
1. PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
Bodhankar S; Chen Y; Lapato A; Dotson AL; Wang J; Vandenbark AA; Saugstad JA; Offner H
Stroke; 2015 Oct; 46(10):2926-34. PubMed ID: 26306753
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
3. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke.
Li P; Mao L; Liu X; Gan Y; Zheng J; Thomson AW; Gao Y; Chen J; Hu X
Stroke; 2014 Mar; 45(3):857-64. PubMed ID: 24496394
[TBL] [Abstract][Full Text] [Related]
4. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Bodhankar S; Chen Y; Lapato A; Vandenbark AA; Murphy SJ; Offner H
Front Cell Neurosci; 2014; 8():228. PubMed ID: 25157219
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
6. Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.
Na SY; Mracsko E; Liesz A; Hünig T; Veltkamp R
Stroke; 2015 Jan; 46(1):212-20. PubMed ID: 25378432
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 (Programmed Death Ligand 1) Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury.
Han R; Luo J; Shi Y; Yao Y; Hao J
Stroke; 2017 Aug; 48(8):2255-2262. PubMed ID: 28706113
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke.
Ren X; Akiyoshi K; Vandenbark AA; Hurn PD; Offner H
Stroke; 2011 Sep; 42(9):2578-83. PubMed ID: 21737801
[TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
11. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
12. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
13. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
14. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
15. The role of Interleukin-33 in the modulation of splenic T-cell immune responses after experimental ischemic stroke.
Xiao W; Guo S; Chen L; Luo Y
J Neuroimmunol; 2019 Aug; 333():576970. PubMed ID: 31146104
[TBL] [Abstract][Full Text] [Related]
16. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load.
da Fonseca-Martins AM; Ramos TD; Pratti JES; Firmino-Cruz L; Gomes DCO; Soong L; Saraiva EM; de Matos Guedes HL
Sci Rep; 2019 Dec; 9(1):20275. PubMed ID: 31889072
[TBL] [Abstract][Full Text] [Related]
18. Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.
Patil NK; Luan L; Bohannon JK; Hernandez A; Guo Y; Sherwood ER
J Leukoc Biol; 2018 Jan; 103(1):23-33. PubMed ID: 29345058
[TBL] [Abstract][Full Text] [Related]
19. Estrogen Signaling in Bystander Foxp3
Garnier L; Laffont S; Lélu K; Yogev N; Waisman A; Guéry JC
J Immunol; 2018 Dec; 201(11):3218-3228. PubMed ID: 30355786
[TBL] [Abstract][Full Text] [Related]
20. FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS; Benonisson H; Breukel C; Visser R; Verhagen OJHM; Bentlage AEH; Brouwers C; Claassens JWC; Linssen MM; Camps M; van Hall T; Ossendorp F; Fransen MF; Vidarsson G; Verbeek JS
Int J Cancer; 2019 Jan; 144(2):345-354. PubMed ID: 30259976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
